1

TEAM STRUCTURE

TEAM NAME : ELIXIR

TEAM MEMBERS : KIKRUSETUO JOHN PIENYU, NIKHIL S

CAMPUS : IIM - KOZHIKODE

BATCH : 2019 – 2021, PGP - 23

 EXECUTIVE SUMMARY
RECOMMENDATION: DIGITAL LINKAGE OF
STAKEHOLDERS CHALLENGES
HEALTHCARE ECOSYSTEM
Private Health Differentiating low value and high value pharmaceutical,
low patient adherence increasing costs
Insurance
stakeholders
Retail
Omissions, patient history, stock and supply chain
Pharmacies issues, reporting incidents and quality management
Low treatment adherence, out of pocket expenditure, low
Patients engagement with PCPs and specialists
Pharma High cost of clinical trials, demand forecasting, increased
Companies pressure for value based pricing
Lack of patient data to provide targeted treatment,
Hospitals patient monitoring, division of labor and productivity
stakeholders
Selecting appropriate insurance product portfolio for
Employer employees. Loss of productivity due to employee illness
and subsequent low adherence to appropriate treatment
High cost of purchase of drugs for public health
Government programs such as Medicare. Monitoring long term
effects of new drugs.
Data can help in outcome based contracts
Input: Data with pharma, reducing costs and risks
from associated with low value pharmaceutical,
financial penalty/reward to patients for
undesirable/desirable behaviors
Online ordering, dispensing history,
marketing, pharmacy locator, medicine
availability and shortages, alternatives
Patient engagement platform via loyalty
points and increased doctor patient
interaction to improve adherence.
Engagement with other patients.
.
Demand insights to optimize production,
Phase IV trials made easier, data sharing
with healthcare providers for improved
outcomes and better positioning of drug
Output:
Optimizes patient time spent in hospitals,
Insights to
optimal allocation of tasks among PCPs,
specialists and other healthcare staff
Reducing costs for plans by eliminating
middlemen such as health insurance
brokers. Employee engagement program
for improving adherence
Data can help in subscription or Netflix
model for purchasing drugs for public
health programs. Accelerated market
(FDA) approval of therapeutics